Abstract 6402: DNA-PK inhibitor, M3814, as a radiation sensitizer in the treatment of neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-6402
Abstract: Despite significant advances in the understanding and managing gastroenteropancreatic neuroendocrine tumors (GEPNETs), the therapeutic success of treatments remains relatively poor. Recent FDA approval of Peptide Receptor Radionuclide Therapy (PRRT) has paved the way for radiation-based… read more here.
Keywords: m3814; treatment; xrt; dna inhibitor ... See more keywords